triazolam has been researched along with Diabetes Mellitus, Type 1 in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As triazolam was administered orally to Tsumura, Suzuki, obese, diabetes (TSOD) mice and streptozotocin (STZ) mice, clearance per body (CL/F) in TSOD mice did not differ compared with Tsumura, Suzuki, non-obesity (TSNO) mice." | 1.36 | Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. ( Ikarashi, N; Kudo, T; Ochiai, W; Ohi, K; Sugiyama, K; Toda, T; Ushiki, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, T | 1 |
| Toda, T | 1 |
| Ushiki, T | 1 |
| Ohi, K | 1 |
| Ikarashi, N | 1 |
| Ochiai, W | 1 |
| Sugiyama, K | 1 |
1 other study available for triazolam and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice.
Topics: Animals; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitu | 2010 |